Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcinosis | 4 | 2006 | 192 | 0.540 |
Why?
|
| Breast Neoplasms | 5 | 2006 | 2648 | 0.420 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2006 | 26 | 0.300 |
Why?
|
| Neck Dissection | 1 | 2007 | 31 | 0.260 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 36 | 0.250 |
Why?
|
| Bacterial Infections | 2 | 2006 | 323 | 0.240 |
Why?
|
| Magnesium Deficiency | 1 | 2005 | 12 | 0.240 |
Why?
|
| Glucuronidase | 1 | 2005 | 30 | 0.240 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 186 | 0.240 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 44 | 0.240 |
Why?
|
| Kv1.3 Potassium Channel | 2 | 2017 | 38 | 0.240 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 123 | 0.240 |
Why?
|
| Magnesium | 1 | 2005 | 114 | 0.230 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 78 | 0.230 |
Why?
|
| Thromboembolism | 1 | 2005 | 93 | 0.220 |
Why?
|
| Antineoplastic Agents | 5 | 2006 | 1825 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2005 | 136 | 0.220 |
Why?
|
| ErbB Receptors | 1 | 2005 | 292 | 0.210 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 172 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 391 | 0.200 |
Why?
|
| Estrogens | 1 | 2005 | 435 | 0.200 |
Why?
|
| Th2 Cells | 2 | 2014 | 188 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 1028 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 622 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 444 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2005 | 609 | 0.170 |
Why?
|
| Potassium Channel Blockers | 2 | 2017 | 86 | 0.160 |
Why?
|
| Stroke | 1 | 2007 | 1085 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 1342 | 0.140 |
Why?
|
| Scorpion Venoms | 1 | 2017 | 14 | 0.130 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 173 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 985 | 0.130 |
Why?
|
| Asthma | 2 | 2014 | 772 | 0.120 |
Why?
|
| Breast Diseases | 2 | 2006 | 39 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 251 | 0.120 |
Why?
|
| Diphosphonates | 2 | 2005 | 43 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 1381 | 0.110 |
Why?
|
| Peptides | 1 | 2017 | 847 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2006 | 719 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 233 | 0.100 |
Why?
|
| Bacteria | 2 | 2006 | 524 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 625 | 0.090 |
Why?
|
| Neoplasms | 1 | 2005 | 2956 | 0.080 |
Why?
|
| Chemokine CXCL12 | 2 | 2006 | 35 | 0.070 |
Why?
|
| Humans | 18 | 2017 | 132132 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2161 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3351 | 0.060 |
Why?
|
| Cetuximab | 1 | 2005 | 13 | 0.060 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2005 | 15 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 1 | 2005 | 17 | 0.060 |
Why?
|
| Hyponatremia | 1 | 2007 | 74 | 0.060 |
Why?
|
| Nanostructures | 1 | 2006 | 64 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2017 | 123 | 0.060 |
Why?
|
| Anthracyclines | 1 | 2005 | 44 | 0.060 |
Why?
|
| Taxoids | 1 | 2005 | 71 | 0.060 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2005 | 31 | 0.060 |
Why?
|
| Female | 10 | 2017 | 70725 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 52 | 0.060 |
Why?
|
| Chemokines | 1 | 2005 | 129 | 0.060 |
Why?
|
| Quinazolines | 1 | 2005 | 176 | 0.060 |
Why?
|
| Mammography | 1 | 2005 | 132 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 230 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 123 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2005 | 553 | 0.050 |
Why?
|
| Ligands | 1 | 2005 | 494 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 343 | 0.050 |
Why?
|
| Breast | 1 | 2005 | 217 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 3093 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4688 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2007 | 800 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 589 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 333 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 1573 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2007 | 716 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2322 | 0.040 |
Why?
|
| Rats | 2 | 2017 | 3611 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 3381 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2017 | 33 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2017 | 70 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2014 | 13034 | 0.030 |
Why?
|
| Terpenes | 1 | 2017 | 30 | 0.030 |
Why?
|
| Arthritis, Experimental | 1 | 2017 | 22 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2017 | 78 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 1738 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 435 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 2917 | 0.030 |
Why?
|
| Biomarkers | 2 | 2017 | 3405 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 270 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 1378 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 354 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1538 | 0.030 |
Why?
|
| Allergens | 1 | 2017 | 276 | 0.030 |
Why?
|
| Arteries | 2 | 2007 | 222 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1254 | 0.030 |
Why?
|
| Animals | 3 | 2017 | 34882 | 0.030 |
Why?
|
| Middle Aged | 4 | 2017 | 29003 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2014 | 47 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2014 | 94 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2014 | 145 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 149 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2014 | 94 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 293 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1500 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 187 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2014 | 196 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 1611 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 2194 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2719 | 0.020 |
Why?
|
| Biological Products | 1 | 2014 | 137 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 791 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 340 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2226 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3036 | 0.020 |
Why?
|
| Young Adult | 2 | 2017 | 9961 | 0.020 |
Why?
|
| Risk Factors | 1 | 2005 | 10949 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2658 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 1036 | 0.020 |
Why?
|
| Aged | 3 | 2017 | 21442 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5169 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 31585 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3739 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 5014 | 0.020 |
Why?
|
| Jugular Veins | 1 | 2007 | 75 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 149 | 0.020 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2005 | 3 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 295 | 0.010 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 56 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2005 | 143 | 0.010 |
Why?
|
| Postmenopause | 1 | 2005 | 153 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2005 | 145 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 136 | 0.010 |
Why?
|
| Heart Valves | 1 | 2005 | 53 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 156 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 392 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 367 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 4529 | 0.010 |
Why?
|
| Male | 3 | 2017 | 64985 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1452 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 1078 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 18507 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 17424 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 3183 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 7108 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 20564 | 0.000 |
Why?
|